At a glance
ClinicalIndex Comparison Record- ✓Healthy healthcare professionals aged 18–60 years
- ✓Regular full-time employees of MUSC Hospital
- ✓Work a 10 or 12 hour work shift
- ✓Test positive for nasal vestibular S. aureus carriage within 10 days prior to study day
- ✕Symptoms of upper respiratory disease, chronic rhinitis/sinusitis, or seasonal allergies
- ✕Upper respiratory infection in the previous 4 weeks
- ✕Known allergy to citrus or soy oil
- ✕Current smoker (smokers defined as those who have not abstained for ≥1 year)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer®
In Brief
A clinical study evaluating Nozin® Nasal Sanitizer® and Placebo for Infectious Disease. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the extent to which bacterial growth in the nostrils by S. aureus, a common bacteria that is found in hospital environment, can be reduced by NOZIN® Nasal Sanitizer® antiseptic nasal swabs during the course of a typical 10-hour work period in participants known to have S. aureus in their nose passages.
Study Details
Timeline
Interventions
The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).